Janssen affiliate Cilag GmbH International has licenced argenx anti-CD70 antibody cusatuzumab (ARGX-110) for US$300m upfront.
Forbion, a European life science venture capital firm, today announces that Carlo Incerti, M.D., will be joining Forbion as Operating Partner, effective 1st January 2019.